+17.6%
SPYM vs MRNA
+485.7%
-468.1%
-8.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 1y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | +5.4% | -4.5% | +0.8% |
| 7D | -0.8% | -1.1% | +0.3% | -0.8% |
| 30D | -1.1% | +126.1% | -127.2% | -2.3% |
| 3M | +3.9% | +190.0% | -186.1% | +0.7% |
| 6M | +13.6% | +157.2% | -143.6% | +10.5% |
| YTD | +12.7% | +388.2% | -375.5% | +6.5% |
| 1Y | +17.6% | +467.0% | -449.4% | +10.1% |
| All | +17.6% | +485.7% | -468.1% | +10.1% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 1y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
1y analysis · Full analysis span regression · 6 months rolling